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Mutations of the Fibroblast Growth Factor Receptor 3 (FGFR3) gene have been implicated in a series of skeletal dysplasias including
hypochondroplasia, achondroplasia and thanatophoric dysplasia. The severity of these diseases ranges from mild dwarfism to severe dwarfism and
to perinatal lethality, respectively. Although it is considered that the mutations give rise to constitutively active receptors, it remains unclear how
the different mutations are functionally linked to the severity of the different pathologies. By examining various FGFR3 mutations in a HEK cell
culture model, including the uncharacterized X807R mutation, it was found that only the mutations affecting the intracellular domain, induced
premature receptor phosphorylation and inhibited receptor glycosylation, suggesting that premature receptor tyrosine phosphorylation of the native
receptor inhibits its glycosylation. Moreover, these mutations appeared to be associated with elevated receptor signaling in the Golgi apparatus. In
conclusion, although pathological severity could not be correlated with a single factor arising from FGFR3 mutations, these results suggest that
intracellular domain mutations define a distinct means by which mutated FGFR3 could disrupt bone development.
© 2007 Elsevier B.V. All rights reserved.Keywords: Chondrodysplasia; Receptor; Kinase; Signaling; Trafficking1. Introduction
Fibroblast Growth Factor Receptor 3 (FGFR3) belongs to a
family of four genes (FGFR1–4) coding for receptor tyrosine
kinases [1]. These proteins constitute a family of structurally
related proteins exhibiting an extracellular domain composed of
three immunoglobulin-like domains, an acid box, a single trans-
membrane domain and a split tyrosine kinase (TK) domain [1].
FGF receptor dimerization and phosphorylation is induced
through the binding of its ligand (FGF) in the presence of
soluble or cell-surface heparan sulfate proteoglycans [2–6]. The
dimer state is stabilized by a conformational change in the
extracellular domain [7]. As a result the two monomers come
into contact. This stimulates catalytic activity resulting in
transphosphorylation of key tyrosine residues in the cytoplas-Abbreviations: ACH, achondroplasia; BFA, Brefeldin A; ER, endoplasmic
reticulum; FGFR, Fibroblast Growth Factor Receptor; HCH, hypochondropla-
sia; TDI and TDII, thanatophoric dysplasia types I and II; TK, tyrosine kinase;
WT, wild type
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doi:10.1016/j.bbamcr.2006.12.010mic domain of the receptor that serve as docking sites for the
adaptor proteins and effectors that propagate FGFR3 signals via
different signaling cascades [8,9].
FGF signaling through FGFR3 is implicated in the regulation
of many cellular processes including proliferation, differentia-
tion, migration, wound healing, and angiogenesis [10,11].
Mutations in FGFR3 have been shown to be responsible for a
variety of skeletal dysplasias [12] of increasing severity,
including achondroplasia (ACH) which is the most common
form of human dwarfism [13,14], the milder disorder hypochon-
droplasia (HCH) [15,16] and the more severe thanatophoric
dysplasia types I and II (TD I and TDII) [13,17,18]. The
thanatophoric dysplasia subdivision arises from the presentation
of curved femurs in TDI but not in TDII. TDIs caused by the
K650M mutation can also be associated with Severe Achon-
droplasia with Developmental Delay and Acanthosis Nigricans
(SADDAN) [19]. These FGFR3 mutations appear to arise from
spontaneous missense neo-mutations [20].
The molecular basis underlying the various chondrodyspla-
sias is thought to be a consequence of the constitutive activation
of mutant receptors [21–23]. These dominant active mutations
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TD in murine transgenic models [24–26].
A number of mechanisms have been proposed to explain how
the mutations affect FGFR3 activation. These include increased
ligand-binding affinity or decreased ligand-mediated receptor
down-regulation in the case of G380R [27] and stabilized ligand-
induced dimers in the case of R248C (TDI) [22,28]. Activating
mutations in the TK domain, such as is the case of the K650N,
K650M and K650E mutations (corresponding to HCH, TDI and
TDII, respectively), lead to ligand-independent receptor activa-
tion and constitutive receptor tyrosine phosphorylation [22].
More recently, two mutations in the murine equivalent of
K650E have been found to inhibit FGFR3 trafficking to the
plasma membrane from the endoplasmic reticulum [29,30].
However it remains unclear how these mechanistic aberrations
relate to disease severity.
The aim of this study was to compare two attributes of mutant
receptor biochemistry (tyrosine phosphorylation and receptor
glycosylation), and the pathology with which the mutation has
been associated. The study analyzed wild type and seven
mutated FGFR3s including the uncharacterized X807R muta-
tion [31], in a HEK cell culture model. Even though all the
mutated receptors were found to have an elevated level of
phosphorylated tyrosine, these levels did not appear to correlate
with disease severity. Tyrosine phosphorylation was identified
on native and partially glycosylated isoforms for the K650N,
K650M, K650E and X807R mutations and appeared to disrupt
glycosylation. However, the degree of defective glycosylation
did not correlate with disease severity. The three K650mutations
and the X807R mutation elicited a high degree of intracellular
tyrosine phosphorylation primarily associated with Rab6-
positive structures suggesting the existence of ectopically
activated signaling cascades associated with the Golgi appara-
tus. The study therefore finds that disease severity of
chondrodysplasias cannot solely be attributed to receptor
activation or receptor activation at the plasma membrane.
2. Materials and methods
2.1. Generation of human FGFR3 constructs
Full length human wild type FGFR3 cDNAwas kindly provided by Dr. M.
Hayman (New York). Single point mutations were generated by site-directed
mutagenesis (Quikchange® Site-Directed Mutagenesis, Stratagene). Enzymes
were purchased from New England Biolabs, Roche Diagnostics and Invitrogen.
Reverse transcriptase-PCR (First Strand Synthesis, Roche Diagnostics) was
performed on patient RNA using primer sets R248C/Y373C-P1/R248C/Y373C-
P2 and G380R-P1/G380R-P2. Site-directed mutagenesis for K650N, K650M
and K650E and X807Rwas performed on wild type FGFR3. All constructs were
cloned into pCDNA3.1 (Invitrogen, Europe). PCR and site-directed mutagenesis
primers are listed in Supplementary Table 1. The presence of mutations was
confirmed by sequencing.
2.2. Western blotting (WB) and immunoprecipitation (IP)
Transfected cells were lysed in RIPA Buffer (50 mM Tris–HCl pH 7.6,
150mMNaCl, 1%Nonidet-P40, 0.5% sodium deoxycholate, supplemented with
protease and phosphatase inhibitors). ForWestern blotting, 20 μg of cell lysate in
RIPA buffer were used. Immunoprecipitation was performed by incubating 1 μg
rabbit anti-FGFR3 (polyclonal against the cytoplasmic domain)/100 μg proteinwith protein G agarose (Roche). Immunoblotting: anti-FGFR3 (Sigma) or mouse
anti-phosphotyrosine (Cell Signaling) were used at a concentration of 1:2000;
secondary antibodies anti-rabbit or anti-mouse HRP (Amersham) were used at a
concentration of 1:10000 and were detected by chemiluminescence (ECL,
Amersham Pharmacia Biotech). Where necessary, PVDF membranes were
stripped in 2% SDS, 100 mM β-mercaptoethanol, 50 mM Tris, pH 6.8.
2.3. Glycosidase treatments
Anti-FGFR3 immunoprecipitates were resuspended in 50mM sodium citrate
(pH 5.5), 1% SDS, 1% β-mercaptoethanol. The sample was divided
proportionally for untreated or EndoH (endoglycosidaseH, Roche) and PNgaseF
(peptide: N-glycosidase F, Roche) treatments, and used according to the man-
ufacturer's instructions.
2.4. Cell culture, transfections and treatments
Human Embryonic Kidney cells (HEK) stably expressing the vitronectin
receptor (293 VnR) were provided by Dr. R. Baron (Yale University). Cells were
incubated in DMEM supplemented with 10% FCS (Invitrogen), and antibiotics.
Transfection of constructs into cells at 50–80% confluency using Fugene6
(Roche)was performed according to themanufacturer's instructions. BrefeldinA
(BFA) treatment: 5 μg/ml for 2 h at 37 °C (Epicentre Technologies; TEBU
France). Nocodazole treatment: 10 μg/ml 2 h at 37 °C (BIOMOL; TEBU,
France). The tyrosine kinase inhibitor Sugen5402 (gift from G. Mc Mahon,
SUGEN) was dissolved in DMSO and used at 25 μM overnight. Control cells
were incubated with DMSO alone. Tunicamycin treatment (5μg/ml; Sigma
Aldrich) was overnight in DMEM supplemented with 10% FCS.
2.5. Immunofluorescence
Transfected cells were fixed in 4% PFA for 20 min, permeabilized in 0.1%
TritonX-100/PBS and blocked in 10% normal sheep serum. Incubation with
primary antibodies; anti-FGFR3 at 1:400; anti-phosphotyrosine at 1:200; rabbit
anti-calnexin at 1:100, (Sigma); mouse anti-GM130 at 1:100, (BD Transduction
Laboratories); rabbit anti-rab6, at 1:100 (Tebu, France); rabbit anti-Sec31, at
1:100 (a gift from Prof. W. Hong), was for 1 h at room temperature. Incubation
with secondary antibodies Alexa488 and Alexa568 at 1:400 (Molecular Probes)
was for 1 h at room temperature. For anti-Rab6; after fixing in PFA, cells were
pre-incubated in 50 mM NH4Cl/PBS for 10 min, with antibody incubation in
0.05% saponin and 0.2% normal sheep serum in PBS.
3. Image analysis and statistics
Experiments were performed on three or more independent
occasions. The quantification ofWestern blotting was performed
using NIH Image. Statistical differences were identified by
application of the Student t test. The variations from the mean
values shown are equal to the Standard Deviations from these
respective means. Immunofluorescence images were selected as
good representatives of the experimental condition.
4. Results
4.1. Glycosylation of FGFR is affected by the K650 mutations
The FGFR3mutations associated with bone growth disorders
are found in different domains and depicted in Fig. 1A. These
include the intracellular domain (K650N/HCH, K650M/TDI,
K650E/TDII, X807R/TDI), the transmembrane domain
(G380R/ACH) and the extracellular domain (R248C/TDI,
Y373C/TDI). The mutation arising from the stop codon read
through (X807R/TDI) is predicted to generate a protein the size
Fig. 1. A biochemical comparison of the glycosylation and tyrosine phosphorylation of the WT and mutant FGFR3s. (A) Schematic depiction of FGFR3 protein
including the Ig-like domains (Ig1–3) of the extracellular domain, the transmembrane domain (TM) and the split tyrosine kinase domains (TK1 and TK2) of the
intracellular domain. Also shown is the position of the mutations examined in this study. (B) FGFR3s for WT, G380R, R248C, Y373C, K650N, K650M and K650E all
appeared as three discrete bands of differing mobilities (105, 115, 130 kDa) by Western blot, as a consequence of glycosylation. EndoH treatment removed mannose-
rich moieties, and PNGase treatment removed all glycosylated moieties from FGFR3. (C) Tunicamycin treatment inhibited glycosylation of native WT and K650M
FGFR3 proteins. (D) The levels of the native and differently glycosylated WT, G380R, R248C, Y373C, K650N, K650M and K650E FGFR3 isoforms were examined
at 24 and 48 h by Western blot (upper panels). The relative levels of the native and differently glycosylated isoforms from at least five experiments were quantified at
24 h (lower graphics). The asterisks mark the significantly lower relative levels of the fully glycosylated isoforms compared with that of the WT (*p<0.01;
**p<0.001). (E) The detection of tyrosine phosphorylation on the FGFR3s. WT, G380R, R248C, Y373C, K650N, K650M and K650E FGFR3s were
immunoprecipitated by anti-FGFR3 and examined by Western blot with anti-FGFR3 or anti-phosphotyrosine. (F) WT and K650M FGFR3s were treated with
Sugen5402 (tyrosine kinase inhibitor) and examined by Western blotting of anti-FGFR3 immunoprecipitations. Sugen5402 treatment reduced tyrosine
phosphorylation and increased the relative level of the fully-glycosylated isoform of the K650M mutant.
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these mutations were analyzed in HEK cells by transient trans-
fection of FGFR3 expression plasmids.
Twenty-four hours post-transfection, FGFR3 protein with
three mobilities was detected byWestern blot analysis of FGFR3
immunoprecipitates from transfected cell extracts (Fig. 1B).
Glycosidase treatments of the protein extracts revealed the wild
type and each of the mutant FGFR3 proteins (R248C, G380R,
Y373C K650N, K650M, K650E) exist as an unglycosylated
form (highest mobility, 105 kDa), an EndoH glycosidase-
sensitive form (intermediate mobility; 115 kDa) and an EndoH
insensitive but PNGase-sensitive form (lowest mobility,
130 kDa). This suggested that FGFR3was subject to progressive
glycosylation from native to fully mature receptor. This was
confirmed by treating the WT and K650M FGFR3 transfected
cells with the N-glycosylation inhibitor tunicamycin. The
inhibition of glycosylation reduced the level of the 115 kDa
and 130 kDa isoforms compared with the untreated controls,
24 h post-transfection (Fig. 1C).
By quantifying the levels of the different FGFR3 glycosy-
lated isoforms at 24 and 48 h, it was found that the relative levels
of the non-glycosylated receptors had declined and the fully
glycosylated receptors had increased at 48 h compared with 24 h
post transfection (p<0.05; Fig. 1D). The proportional level offully glycosylated receptors found with the WT receptor at 24 h
(38±8%, n=15) was similar to that found with R248C (35±
16%, n=8), G380R (36±12%, n=5), Y373C (37±11%, n=6)
mutations. However the proportional level of fully glycosylated
receptors found with K650N (24±9%, n=5), K650M (7±4%,
n=10) and K650E (4±4%, n=10) was significantly less than
that found with the WT, whereas the proportional level of non-
glycosylated K650M (31±8%) and K650E (33±15%) recep-
tors, was significantly greater than that found with the WT (12±
7%). This suggested that mutations associated with amino acid
K650 of the intracellular domain inhibited glycosylation and the
mutations that occur in the transmembrane or extracellular do-
mains do not inhibit glycosylation.
4.2. Receptor phosphorylation is greater for FGFR3 with
intracellular mutations
To examine the relationship between glycosylation and
receptor tyrosine phosphorylation, anti-FGFR3 immunopreci-
pitates of transfected cells were probed with a phosphotyrosine
antibody on Western blots (Fig. 1E). A low level of phos-
photyrosine was detected on the wild type receptor. Amarginally
greater level of tyrosine phosphorylated FGFR3 was found with
the G380R, R248C and Y373C mutants. The level of tyrosine
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tants, where K650M>K650E>K650N. Moreover phosphotyr-
osine was detected primarily on the fully glycosylated isoforms
of the WT, G380R, R248C, Y373C FGFRs whereas phos-
photyrosine was also detected on the non- and partially glyco-
sylated K650 mutant isoforms. These results suggested that
tyrosine phosphorylation of the K650 mutants in their non-
or partially-glycosylated forms, inhibits their further glyco-
sylation. This is especially so for K650M and K650E, and
less marked for K650N. This suggestion was supported by ana-
lyzing cells transfected with either the WT or K650M mutant
FGFR3s following treatment with the tyrosine kinase inhibi-
tor Sugen5402 (Fig. 1F). Following Western blot of FGFR3
immunoprecipitates, it was found that the level of tyro-
sine phosphorylated FGFR3 was strongly reduced, although
some tyrosine phosphorylated FGFR3 was detected with the
K650M mutant (Fig. 1F). The reduction of tyrosine phos-
phorylation of the K650Mmutant FGFR3 was associated with a
large relative increase in the level of fully glycosylated iso-
form. Such a relative increase in the level of fully glycosylated
isoform was not detected in cells transfected with the wild type
receptor.
The degree of glycosylation and of tyrosine phosphorylation
of the FGFR3 mutants were compared with pathology severity
(Table 1). Pathology severity was ranked in accordance to what
has been described for the long bone dysplasia, placing the TDI
and TDII with equal but most severe rank [32,33]. It was found
that there was no simple or significant correlation between these
factors and the severity of the disease pathology associated with
the different mutations. However the analysis suggested that the
K650 mutations function differently to those mutations
affecting the transmembrane or extracellular domains where
the pathology severity is positively correlated with the degree of
disrupted receptor glycosylation (r2=0.97).
4.3. The X807R mutation affects FGFR3 glycosylation
The FGFR3 stop codon read-through mutation X807R, was
identified in the TDI pathology but its functional relationship to
the pathology is not known. Three FGFR3 isoforms of differing
mobilities were detected in cells transfected with the X807RTable 1
No statistically significant correlation between bone pathologies from which the
FGFR3 mutations arise, and glycosylation processing defects or the level of
tyrosine phosphorylation




WT none 1 1 1
K650N HCH 2 2 2
G380R ACH 3 1 1
R248C TDI 4 1 1
Y373C TDI 4 1 1
K650M TDI 4 4 3
K650E TDII 4 3 3
Correlation coefficient with pathology, r2 0.13 0.11
The table lists the ranking scores for each parameter used, prior to determining
the correlation coefficient r2.mutant (Fig. 2B). The X807R mutant was found to exist as
unglycosylated and glycosylated forms. The intermediate
mobility isoform was both PNGase and EndoH sensitive and
the lowest mobility isoform was PNGase sensitive but endoH
insensitive. The size of the X807R isoforms suggested that they
all included the predicted 141 amino residue read-through. By
quantifying the levels of the different isoforms 24 h post-
transfection, it was found that the relative level of fully
glycosylated isoform (12±9%, n=8) was similar to what was
found with the K650M and K650E mutants and significantly
lower thanwhat was foundwith theWTreceptor (Fig. 2C and see
Fig. 1D). Also consistent with an inhibition of glycosylation, the
relative level of non-glycosylated X807R mutant receptor (49±
15%) was significantly greater than that found with the WT. The
X807R mutant was also found to be tyrosine phosphorylated on
the non- and partially-glycosylated isoforms (Fig. 2D). Therefore
this suggested that the X807R confers a constitutively active
status to FGFR3. Moreover X807R was found have similar
characteristics to the other intracellular domain mutations
(K650N, K605E and K650M) suggesting that the intracellular
mutations enable tyrosine phosphorylation prior to glycosylation.
4.4. Greater levels of phosphotyrosine-positive puncta occur
with the intracellular FGFR3 mutations
The process of protein glycosylation is related to trafficking
through the endoplasmic reticulum and Golgi apparatus.
Typically, the glycosylation that is EndoH sensitive takes place
in the endoplasmic reticulum whereas glycosylation insensitive
to EndoH takes place in the Golgi apparatus. Using immuno-
fluorescence to examine cells 24 h post-transfection, it was found
that the wild type and the mutant FGFR3s were associated with
intracellular structures throughout the cytoplasm. In every case
there was some co-localization of these structures and punctate
structures detected by the Golgi marker antibody, GM130 (Fig.
2E). This suggested that the resistance of the K650N, K650E,
K650M and X807R mutants to complete glycosylation was not
because they were prevented from reaching the Golgi apparatus.
Given that receptor tyrosine phosphorylation was also found
to inhibit receptor glycosylation, a phosphotyrosine antibody
was used for immunofluorescence (Fig. 3A). High phosphotyr-
osine levels were essentially associated with FGFR3 transfected
cells (with a low level occasionally detectable in untransfected
cells). The punctate structures detected by the phosphotyrosine
antibody also co-localized with some of the intracellular
structures detected by the FGFR3 antibody suggesting that
these punctate structures include tyrosine phosphorylated
FGFR3. The intensity and the extent of phosphotyrosine-
positive puncta appeared greater in the K650N, K650E,
K650M and the X807R mutants compared with the other
mutants and the wild type FGFRs (Fig. 3B).
4.5. Phosphotyrosine-positive puncta are distinctly associated
with the Golgi apparatus
In order to attempt to identify whether the phosphotyrosine
activity of FGFR3 is associated with subcellular sites of
Fig. 2. The intracellular mutation X807R displays similar biochemical properties to those of the K650 mutations. (A) Schematic representation of the X807R mutation
with the additional read-through domain of the FGFR3 protein that includes a hydrophobic rich region. (B) The X807R FGFR3 appeared as three discrete bands of
differing mobilities (approximately 128,139,153 kDa) by Western blot, as a consequence of glycosylation. EndoH treatment removed mannose-rich moieties, and
PNGase treatment removed all glycosylated moieties from FGFR3. (C) The relative levels of the native and differently glycosylated X807R FGFR3s from eight
experiments were quantified at 24 h, where the relative level of the lowest mobility isoform (153 kDa and marked by asterisks) was significantly lower than that of the
WT receptor (**p<0.001). (D) Tyrosine phosphorylation on the X807R FGFR3 mutation was assessed by immunoprecipitation by anti-FGFR3 and examined by
Western blot with anti-FGFR3 or anti-phosphotyrosine. (E) The X807R, K650M andWT receptors detected by immunofluorescence (green) partially colocalised with
the Golgi marker GM130 (red). Scale bars equal 2 μm. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of
this article.)
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was compared with markers of the ER (calnexin), of ER exit
(sec31) [34] and of the Golgi apparatus (rab6) [35] (Fig. 4).
Calnexin was associated with structures throughout the
cytoplasm as expected for a protein expressed in the ER (it
retains unfolded or unassembled N-linked glycoproteins in the
ER). Few of the low level of phosphotyrosine-positive puncta
co-localized with cells transfected with the wild type FGFR3.
However there appeared to be proportionally more co-localiza-
tion of phosphotyrosine-positive puncta with calnexin in the
K650M and X807R mutants. Sec31 was detected as punctate
structures throughout the cytoplasm as expected for a protein
involved in the transport of proteins from the ER to the Golgiapparatus. There was little colocalization of phosphotyrosine-
positive punctawith sec31 in the cells transfected with wild type
and X807R FGFR3s, but some co-localization was seen in the
cells transfected with K650M. Rab6-positive puncta were
identified as being restricted to a portion of the cytoplasm
proximal to an aspect of the nucleus expected for a protein
associated with different parts of the Golgi (medial, trans-Golgi
network and post-Golgi vesicles). In all FGFR3-transfected
cells a high proportion of phosphotyrosine-positive puncta
appeared co-localized with rab6. Therefore, phosphotyrosine
activity arising from FGFR3 transfection appeared mainly
associated with the Golgi apparatus in comparison to the other
intracellular structures examined.
Fig. 3. The expression of FGFR3 is associated with elevated levels of tyrosine phosphorylated proteins. (A) Immunofluorescence detection of FGFR3 (green) and
tyrosine phosphorylated proteins (red) revealed that detectable levels of tyrosine phosphorylation are only associated with FGFR3-transfected cells exemplified here
by cells transiently transfected with the WT and K650M FGFR3 variants. The nuclei (blue) of non-transfected cells are marked by asterisks. (B) The levels of
detectable tyrosine phosphorylated proteins varied depending upon the construct that was transfected (WT, G380R, Y373C, K650N, K650M, K650E and X807R
FGFR3s). Scale bars equal 2 μm. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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Fig. 4. Greater association of FGFR3-positive puncta (green) in WT, K650M or X807R transfected cells, with rab6-positive puncta (red, lower nine panels) compared
with calnexin (red, upper nine panels) or sec31-positive puncta (red, middle nine panels). Scale bars equal 2 μm. (For interpretation of the references to colour in this
figure legend, the reader is referred to the web version of this article.)
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puncta
To further examine whether the phosphotyrosine-positive
puncta were mainly associated with the Golgi apparatus,
transfected cells were treated with nocodazole. Nocodazole
affects microtubule stability and therefore disrupts Golgi
apparatus positioning in the cell without affecting its function.
Treatment with nocadazole did not appear to affect the relative
level of fully glycosylated receptor in cells transfected with
wild type or K650M FGFR3s (Fig. 5A). Analysis by
immunofluorescence found that nocodazole treatment led to
phosphotyrosine-positive puncta being more scattered
throughout the cytoplasm in the cells transfected with wild
type and K650M and X807R FGFR3s (Fig. 5B). ThereforeFig. 5. Treatments of FGFR3-transfected cells with nocodazole or BFA suggest tha
apparatus. (A) Western analysis of transfected cells with either the WT or K650M
Immunofluorescence detection of FGFR3 (green) and tyrosine phosphorylated protein
nocodazole. (C) Western analysis of transfected cells with either the WT, G380R, Y3
glycosylation. (D) Immunofluorescence detection of FGFR3 (green) and tyrosine pho
K650M or K650E isoforms and treated with BFA. Scale bars equal 2 μm. (For interpre
web version of this article.)these results further support that the phosphotyrosine activity
associated with FGFR3 transfection is associated with the
Golgi apparatus.
4.7. BrefeldinA inhibits glycosylation and the number of
phosphotyrosine-positive puncta
BFA reversibly disrupts Golgi apparatus function by inhibi-
ting the anterograde transport from the endoplasmic reticulum
to the Golgi apparatus. BFA treatment reduced the relative level
of the fully glycosylated FGFR3 especially notable in the cells
transfected with the wild type, G380R, Y373C and K650N
receptors where the levels of the fully glycosylated isoforms
in the untreated samples were relatively high (Fig. 5C). As
expected, this suggested that the glycosylation processing wast the tyrosine phosphorylated proteins are primarily associated with the Golgi
isoforms and treated with nocodazole, shows no change in glycosylation. (B)
s (red) of cells transfected with WT, K650M or X807R isoforms and treated with
73C, K650N, K650M or K650E isoforms showing that BFA treatment inhibits
sphorylated proteins (red) of cells transfected with WT, G380R, Y373C, K650N,
tation of the references to colour in this figure legend, the reader is referred to the
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from leaving the ER on its route to the Golgi apparatus.
Analysis by immunofluorescence suggested that the level of
intensity and number of phosphotyrosine-positive puncta were
dramatically reduced following treatment with BFA in FGFR3-
transfected cells (Fig. 5D). This again suggested that the
induction of phosphotyrosine levels primarily occurs post-ER
and hence in the Golgi apparatus. However, despite the
generally large reduction of phosphotyrosine immunoreactivity,
more was found in those cells transfected with the three K650
mutants and with X807R compared with the cells transfected
with the wild type, G380R and Y373C. This suggested that the
phosphotyrosine detected in the cells treated with BFA and
transfected with the K650 and X807R mutants may have arisen
from those receptors that have yet to be glycosylated, as
detected by immunoprecipitation (Figs. 1E and 2C).
5. Discussion
Spontaneous missense neo-mutations in FGFR3 are respon-
sible for chondrodysplasias such as HCH, ACH, TDI and
TDII. Several mutations affecting particular amino acid
residues of the receptor have now been identified. The
analysis of the X807R mutation further supports the idea that
these mutations promote receptor tyrosine phosphorylation
[32], and presumably promote concomitant tyrosine phos-
phorylation of other protein substrates. The X807R represents
a different type of mutation compared with the other
characterized mutations, in that due to a read-through of the
stop codon. The resultant predicted protein sequence has an
elongated C-terminal domain. This additional C-terminal
domain may function by stabilizing tyrosine phosphorylation,
perhaps by inducing some form of conformational change that
is similar to that described for the K650 mutations [21,26].
The detection of tyrosine phosphorylation was found in a
similar fashion to that of the K650 mutated receptors, being
found on the non- and partially-glycosylated X807R mutated
receptor.
Further receptor tyrosine phosphorylation with any of the
mutated receptors, could not be provoked by the addition of
FGF ligand suggesting a limitation of this HEK model.
However the fact that tyrosine phosphorylation was detected
with all the receptors suggested that they have the capacity of
being phosphorylated in the absence of ligand. Another
potential problem with a transient transfection model is that
over-expressed proteins could accumulate in the ER. This may
have occurred with this study as the immunodetection of the
WT and mutated FGFR3s were found in structures throughout
the cytoplasm and was similar to that of the ER marker calnexin
(compare anti-FGFR3 in Figs. 2 and 3 with that of anti-calnexin
in Fig. 4). Some of these structures though, were also marked by
the Golgi marker GM130, suggesting that all the receptors could
traffic from the ER to the Golgi apparatus. This trafficking step
is indicative of correct receptor folding and N-glycosylation
[36]. By quantifying the FGFR3 isoform levels of the WT and
mutated receptors at 24 and 48 h post-transfection suggested
that the correct progression of glycosylation could occur in thismodel, with the relative level of the non-glycosylated FGFR3
isoform decreasing in all the receptors when examined at 48 h.
Moreover this analysis indicated that these glycosylation steps
were significantly disrupted only in the cells transfected with
K650N, M and E, and X807R mutated FGFR3s.
The western analysis also found that those mutations located
in the intracellular domain resulted in the tyrosine-phosphor-
ylation of non- and partially-glycosylated receptor isoforms.
This biochemical difference was corroborated by the immuno-
fluorescence analysis, where it was found that these receptors
also appeared associated with an enhanced level of tyrosine-
phosphorylated proteins in intracellular structures that had
properties consistent with being components of the Golgi ap-
paratus. This suggested that those mutations located in the
intracellular domain provoke premature phosphorylation of the
de novo receptor.
This premature phosphorylation also appeared to inhibit
receptor glycosylation, concurring with previous analyses of the
murine equivalents of the K650 mutations [29,30]. In contrast to
these previous studies where it has been suggested that these
constitutively active mutated murine receptors accumulate in
the ER, the results here suggest a model where the constitutively
active human receptors, mutated in the intracellular domain,
accumulate in the Golgi apparatus, where they promote further
tyrosine phosphorylation. In this study phosphotyrosine was
used as a readout of FGFR3 activity, whereas in previous
studies, particular tyrosine phosphorylated FGFR3 targets such
as Stat1, Stat3, Stat5, Jak1 and ERK1/2 were analysed [30,37].
One of these studies suggested that murine equivalents of K650
M and E phosphorylate these proteins in the ER because their
detection was insensitive to BFA treatment. In this study, BFA
did not completely extinguish the immunodetection of phos-
photyrosine and therefore the phosphotyrosine antibody may
have detected these FGFR3 targets. One potential FGFR3
signaling molecule post-ER in the case of K650N alone, could
be Stat1 [30]. The murine equivalent of K650N FGFR3 was
found to stimulate Stat1 phosphorylation with and without the
post-Golgi trafficking inhibitor monensin, but was found not
stimulate Stat1 phosphorylation with BFA treatment (unlike the
murine equivalents of K650 M and E) [30,37]. Therefore this
suggests that the phosphotyrosine detected in the Golgi by
immunofluorescence in this study, especially in the cases of
K650M, E and X807R, is either mainly derived from the
FGFR3 itself or from other FGFR3 phosphotyrosine targets yet
to be identified.
Hence, the receptors with intracellular domain mutations
define a distinct means by which mutated FGFR3 can disrupt
bone development, through enhanced and ectopic signaling
emanating from the Golgi apparatus. This may explain why
the correlation between the degree disrupted receptor glyco-
sylation and pathology severity may only hold for the K650
mutated receptors. Moreover this study predicts that the
X807R mutations gives rise to bone dysplasia by a similar
mechanism to that found with the K650 mutations. It also
seems clear that other factors in addition to tyrosine
phosphorylation and disrupted receptor glycosylation are
implicated in the severity of the disease; and one additional
511L. Gibbs, L. Legeai-Mallet / Biochimica et Biophysica Acta 1773 (2007) 502–512factor includes the intracellular localization of receptor activity
to the Golgi apparatus.
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